



Public Health
England

cancer52
the common voice
for less common cancers

Protecting and improving the nation's health

National Cancer Intelligence Network Rare and Less Common Cancers

Incidence and Mortality in England, 2010-2013

An extract from NCIN's workbook showing ICD-10 coding, incidence and mortality data for the Upper Gastrointestinal cancers, including cholangiocarcinoma, for the individual years 2010-2013.



www.ammf.org.uk

The Rare and Less Common Cancers Report

A new report produced jointly by the NCIN (National Cancer Intelligence Network) at Public Health England and Cancer52¹, “Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013” was published on 8th June 2015.

This new report gathers data for the first time on nearly 280 rare and less common cancers in one document. Incidence and mortality rates over the four years 2010-2013 for England are included for some of the rare cancers for the first time.

The full report is available from:

http://www.ncin.org.uk/publications/rare_and_less_common_cancers

The following pages show the data AMMF has extracted from NCIN’s workbook² for incidence and mortality for the individual years 2010-2013, together with male/female breakdown, for the Upper Gastrointestinal cancers, including cholangiocarcinoma.

For the first time, the four ICD-10 codings for cholangiocarcinoma have been grouped, giving more accurate incidence and mortality figures than ever before.

Comment taken from the Executive Summary of the report:

“ ... Upper GI cancers including pancreatic cancer and biliary tract cancers (cholangiocarcinoma/bile duct cancer (intra- or extrahepatic)) also had high mortality rates given their incidence, 13.10 vs. 14.05 and 3.64 vs. 3.58 per 100,000 population respectively. Examining these differences in more detail, and assessing any changes in the quality of cancer registration data over time may help to unpick the variation seen here.”

(All figures are for England only. Data from the other countries of the UK will be included in the next stage of the report.)

¹ Cancer52 – an alliance of some 80 of the rare and less common cancer organisations working to address inequality and improve outcomes for patients with these highly challenging diseases. AMMF – The Cholangiocarcinoma Charity (www.ammf.org.uk) is an active member of Cancer52, and Helen Morement is a board director. <http://www.cancer52.org.uk/>

² The workbook is available from NCIN’s website:
http://www.ncin.org.uk/publications/rare_and_less_common_cancers



Upper Gastrointestinal Cancers ICD-10 Coding

The following tables show the site groupings used and their ICD-10 codes

General Group	Incidence Groups: Group or site name	ICD10 codes
UGI	Ampulla of Vater	C24.1
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	C22.1, C24.0, C24.8, C24.9
	Duodenal cancer	C17.0
	Gallbladder cancer	C23
	Pancreas	C25
	Primary liver (excluding intrahepatic bile duct cancer)	C22.0, C22.2 – C22.9

General Group	Mortality Groups: Group or site name	ICD10 codes
UGI	Ampulla of Vater	C24.1
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	C22.1, C24.0, C24.8, C24.9
	Duodenal cancer	C17.0
	Gallbladder cancer	C23
	Pancreas	C25
	Primary liver (excluding intrahepatic bile duct cancer)	C22.0, C22.2 – C22.9

Crude Incidence (for England only)

Number of
incident
cases

Incidence
rate per
100,000
population

2010	Ampulla of Vater	374	0.72
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,832	3.51
	Duodenal cancer	390	0.75
	Gallbladder cancer	623	1.19
	Pancreas	7,112	13.62
	Primary liver (excluding intrahepatic bile duct cancer)	2,256	4.32
2011	Ampulla of Vater	376	0.71
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,864	3.51
	Duodenal cancer	409	0.77
	Gallbladder cancer	644	1.21
	Pancreas	7,234	13.62
	Primary liver (excluding intrahepatic bile duct cancer)	2,116	3.98
2012	Ampulla of Vater	387	0.72
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,945	3.64
	Duodenal cancer	436	0.82
	Gallbladder cancer	696	1.30
	Pancreas	7,730	14.45
	Primary liver (excluding intrahepatic bile duct cancer)	2,641	4.94
2013	Ampulla of Vater	432	0.80
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,965	3.65
	Duodenal cancer	465	0.86
	Gallbladder cancer	751	1.39
	Pancreas	7,816	14.51
	Primary liver (excluding intrahepatic bile duct cancer)	2,889	5.36
2010-2013	Ampulla of Vater	1,569	0.74
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	7,606	3.58
	Duodenal cancer	1,700	0.80
	Gallbladder cancer	2,714	1.28
	Pancreas	29,892	14.05
	Primary liver (excluding intrahepatic bile duct cancer)	9,902	4.66

Crude Mortality (for England only)

Number of
deaths

Mortality
rate per
100,000
population

		Number of deaths	Mortality rate per 100,000 population
2010	Ampulla of Vater	56	0.11
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,720	3.29
	Duodenal cancer	222	0.43
	Gallbladder cancer	408	0.78
	Pancreas	6,596	12.63
	Primary liver (excluding intrahepatic bile duct cancer)	1,540	2.95
2011	Ampulla of Vater	91	0.17
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	1,844	3.47
	Duodenal cancer	217	0.41
	Gallbladder cancer	432	0.81
	Pancreas	6,954	13.09
	Primary liver (excluding intrahepatic bile duct cancer)	1,651	3.11
2012	Ampulla of Vater	102	0.19
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	2,018	3.77
	Duodenal cancer	217	0.41
	Gallbladder cancer	420	0.79
	Pancreas	7,231	13.52
	Primary liver (excluding intrahepatic bile duct cancer)	1,852	3.46
2013	Ampulla of Vater	103	0.19
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	2,161	4.01
	Duodenal cancer	256	0.48
	Gallbladder cancer	438	0.81
	Pancreas	7,088	13.16
	Primary liver (excluding intrahepatic bile duct cancer)	1,856	3.45
2010-2013	Ampulla of Vater	352	0.17
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	7,743	3.64
	Duodenal cancer	912	0.43
	Gallbladder cancer	1,698	0.80
	Pancreas	27,869	13.10
	Primary liver (excluding intrahepatic bile duct cancer)	6,899	3.24

Persons Incidence 2010-2013		Number of incident cases	Incidence rate per 100,000 population
------------------------------------	--	---------------------------------	--

Male	Ampulla of Vater	845	0.81
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	3,670	3.50
	Duodenal cancer	908	0.87
	Gallbladder cancer	782	0.75
	Pancreas	14,923	14.25
	Primary liver (excluding intrahepatic bile duct cancer)	7,186	6.86

Female	Ampulla of Vater	724	0.67
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	3,936	3.65
	Duodenal cancer	792	0.73
	Gallbladder cancer	1,932	1.79
	Pancreas	14,969	13.87
	Primary liver (excluding intrahepatic bile duct cancer)	2,716	2.52

Persons Mortality 2010-2013		Number of deaths	Mortality rate per 100,000 population
------------------------------------	--	-------------------------	--

Male	Ampulla of Vater	167	0.16
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	3,526	3.37
	Duodenal cancer	489	0.47
	Gallbladder cancer	462	0.44
	Pancreas	13,857	13.23
	Primary liver (excluding intrahepatic bile duct cancer)	5,099	4.87

Female	Ampulla of Vater	185	0.17
	Biliary tract cancer (or cholangiocarcinoma or bile duct cancer (intra- or extrahepatic))	4,217	3.91
	Duodenal cancer	423	0.39
	Gallbladder cancer	1,236	1.15
	Pancreas	14,012	12.98
	Primary liver (excluding intrahepatic bile duct cancer)	1,800	1.67